4th October 2022
Polar Capital Global Healthcare Trust plc (the "Company")
Top Ten Equity Holdings and Sector and Geographic Exposure as at 30th September 2022 and full Portfolio listing as at 31st August 2022 available from company's website
Polar Capital Global Healthcare Trust plc is pleased to announce that as at 30th September 2022 the top ten equity holdings and the sector and geographic breakdown were as follows:
Top 10 Holdings | % |
Johnson & Johnson | 8.9% |
UnitedHealth Group | 7.3% |
AbbVie | 6.2% |
AstraZeneca | 4.9% |
Eli Lilly & Co | 4.2% |
Cytokinetics | 3.6% |
Boston Scientific Corp | 3.5% |
Novartis | 3.5% |
Humana | 3.4% |
Alcon | 3.0% |
Total | 48.4% |
Sector Exposure | % |
Pharmaceuticals | 31.2% |
Biotechnology | 28.3% |
Managed Healthcare | 13.1% |
Healthcare Equipment | 12.1% |
Healthcare Facilities | 7.4% |
Life Sciences Tools & Services | 4.4% |
Healthcare Supplies | 3.0% |
Metal & Glass Containers | 2.4% |
Healthcare Services | 2.1% |
Healthcare Distributors | 1.9% |
Cash | -7.3% |
Total | 100.0% |
Geographic Exposure | % |
United States | 72.2% |
Japan | 6.8% |
Switzerland | 6.5% |
United Kingdom | 6.4% |
Denmark | 4.4% |
Sweden | 2.9% |
France | 2.6% |
Netherlands | 2.3% |
Germany | 2.2% |
Ireland | 1.0% |
Cash | -7.3% |
Total | 100.0% |
Gearing Ratio as calculated in accordance with the guidelines of the Association of Investment Companies, was 7.4%. Gearing is made up of structural debt provided by the subsidiary company PCGH ZDP plc, through the issue of zero dividend preference (ZDP) shares.
The ZDP asset cover as at 30th September 2022 was 11.19x. This ratio is calculated by dividing the Company's net asset value, adjusted to add back the current value of the structural debt, by the final redemption value of the ZDP shares.
The monthly factsheet will usually be available on the Company's website on the 10th working day after the month end and includes a commentary by the investment manager. www.Polarcapitalhealthcaretrust.com
Neither the contents of the Company's website nor the contents of any website accessible from the hyperlinks on the Company's website (or any other website) is incorporated into or forms part of this announcement.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.